Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2019
Price : $35 *
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms STEP 3
- Sponsors Novo Nordisk
- 30 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2018 According to a Novo Nordisk media release, all four STEP trials are expected to be completed in 2020.
- 07 Aug 2018 New trial record